Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Imatinib-Resistant/Intolerant Lymphoid Blast Phase CML or Ph+ ALL
NCT00101595Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2005
- Primary completion
- Dec 2007
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 20
01
Overview
A Phase 2 trial of dasatinib in Chronic Myeloid Leukemia, Lymphoid Blast Phase (CML-LBP), Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by Bristol Myers Squibb. Started Jan 2005; status: completed.
02
Drugs
dasatinib
03
Conditions
Chronic Myeloid Leukemia, Lymphoid Blast Phase (CML-LBP)Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT00101595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00101595.